EXAS' third-quarter 2024 top line benefits from broad-based momentum in Cologuard adoption and Oncotype DX's international ...

Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

Exact Sciences (NASDAQ:EXAS – Get Free Report) had its price target boosted by stock analysts at Canaccord Genuity Group from ...

On Tuesday, Exact Sciences Corp. (NASDAQ:EXAS) reported a third-quarter EPS loss of $0.21, compared to a break-even a year ago, missing the analyst consensus loss estimate of $0.20. The reported ...

BofA lowered the firm’s price target on Exact Sciences (EXAS) to $75 from $88 and keeps a Buy rating on the shares after the company ...

Wells Fargo analyst Brandon Couillard assigned a Buy rating to Exact Sciences (EXAS – Research Report) yesterday and set a price target ...

Shares of Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) gapped down prior to trading on Wednesday after the company ...

On Wednesday, Exact Sciences Corp (EXAS) stock saw a decline, ending the day at $54.72 which represents a decrease of $-16.79 or -23.48% from the prior close of $71.51. The stock opened at $55.7 and ...

On Monday, Exact Sciences Corp (EXAS) stock saw a modest uptick, ending the day at $71.13 which represents a slight increase of $1.33 or 1.91% from the prior close of $69.8. The stock opened at $69.53 ...

Trump Media Stock Volatile On Election Eve As Polls, Betting Markets Predict Tight White House Race Outlook: Exact Sciences sees fiscal year 2024 total revenue in a range of $2.73 billion to $2.75 ...

At this time, I would like to welcome everyone to the Exact Sciences third-quarter 2024 earnings conference call. [Operator ...